Includes Special Report on Global COVID-19 Response and Commitment to Diversity & Inclusion LAVAL, QC Sept. 23, 2020 CNW -- Bausch Health Companies Inc. today released its annual Corporate Social Responsibility Report highlighting the Company's ongoing commitment to responsible, ethical and sustainable operations in 2019. In addition to outlining initiatives and key performance indicators in 2019, the report ...

Includes Special Report on Global COVID-19 Response and Commitment to Diversity & Inclusion

LAVAL, QC , Sept. 23, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today released its annual Corporate Social Responsibility (CSR) Report , highlighting the Company's ongoing commitment to responsible, ethical and sustainable operations in 2019. In addition to outlining initiatives and key performance indicators in 2019, the report features an early look at 2020 efforts, including the Company's COVID-19 response efforts in the first half of 2020 and its Diversity & Inclusion (D&I) initiatives.

"Now more than ever, we recognize the increased importance of corporate citizenship in creating an environment where our employees, our customers, our partners and our communities can thrive," said Joseph C. Papa , chairman and CEO, Bausch Health . "As we continue to improve sustainability and raise the bar on our ethical, social and operational standards, we are furthering our mission to improve lives and advance global health."

The 2019 CSR report also includes other global efforts in the Company's five key commitment areas: operate with integrity; respect the environment; advance global health and patient care; improve communities; and support employee growth and well-being. Additionally, the report includes the highlights of charitable giving efforts directed by the Bausch Foundation, as detailed in the Bausch Foundation Inaugural Activity Report released earlier this month.

2019 CSR highlights include:

  • Reductions in energy usage, water usage, waste production and carbon emissions at Bausch Health facilities
    • Establishment of Energy Efficiency Group (EEG) to analyze and improve energy consumption globally
    • Installation of new nitrogen-generating plant in Waterford, Ireland , reducing future carbon dioxide emissions by nearly 200 tons per year
  • Collaborations, financial contributions and product donations to global charitable health organizations and patient advocacy groups
  • Continued commitment to patient access and responsible pricing, including that the average annual price increase for branded prescription products would be set at no greater than single digits
  • Continuing to support provider education, research grants and charitable organizations devoted to improving patient care and quality of life, and advancing the safety and effectiveness of healthcare products

The full report can be viewed in the Responsibility section of Bausch Health's website at https://www.bauschhealth.com/responsibility .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 856-3855

(908) 927-1198

(877) 281-6642 (toll free)


Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/bausch-health-releases-annual-corporate-social-responsibility-report-301136096.html

SOURCE Bausch Health Companies Inc.

News Provided by Canada Newswire via QuoteMedia

Janssen to Showcase Progress on Respiratory Syncytial Virus Vaccine Candidate at ESWI 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) today announced it will present data from six company-sponsored studies in support of their respiratory syncytial virus (RSV) adult vaccine candidate at the Eighth European Scientific Working Group on Influenza (ESWI) meeting . The cornerstone of Janssen's presence at ESWI will be a series of presentations detailing findings from the Phase 2b CYPRESS trial in adults at increased risk for RSV.

Keep reading... Show less

Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month

Opioid-Induced Constipation Takes the Spotlight on TikTok

Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation Initiatives Aim to Spark Greater Awareness for These Conditions

Keep reading... Show less

Knight to Present at Stifel GMP's The Future of Healthcare Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, is pleased to announce that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the upcoming Stifel GMP Future of Healthcare Conference on Wednesday, December 8, 2021 at 10 am ET, that will be held virtually. A live webcast of the event will be available at the following link: Event . A copy of the presentation will be available at www.gud-knight.com .

About Knight Therapeutics Inc.

Keep reading... Show less

IDBS Polar Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

Keep reading... Show less

Medtronic receives Health Canada licence for GI Genius intelligent endoscopy module with artificial intelligence system for colonoscopy

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

Keep reading... Show less
Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").

Keep reading... Show less

Top News

Related News